# The New Horizon: A Viewpoint of Novel Drugs, Biomarkers, Artificial Intelligence, and Self-Management in Improving Kidney Transplant Outcomes

## TL;DR

This paper explores how new drugs, biomarkers, AI, and self-management can improve kidney transplant success and longevity.

## Contribution

The paper introduces a novel perspective combining drugs, biomarkers, AI, and self-management for better kidney transplant outcomes.

## Key findings

- SGLT2 inhibitors and finerenone show promise but need long-term evidence in kidney transplant patients.
- Biomarkers and AI can improve early detection and personalized treatment in kidney transplants.
- Home-based technologies may enhance transplant success by addressing self-management and health disparities.

## Abstract

The increasing prevalence of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) has led to a growing demand for kidney transplantation (KTx). Identifying risk factors that enable improved allograft survival through novel therapeutic agents, advanced biomarkers, and artificial intelligence (AI)-driven data integration are critical to addressing this challenge. Drugs, such as SGLT2 inhibitors and finerenone, have demonstrated improved outcomes in patients but lack comprehensive long-term evidence in KTx patients. The use of biomarkers, including circulating cytokines and transcriptomics, coupled with AI, could enhance early detection and personalized treatment strategies. Addressing patient self-management and addressing health access disparities may be more achievable using technologies used at home rather than traditional models of healthcare and thus lead to increased transplant success, both in terms of transplantation rates and allograft longevity.